BiotechTube

DE-114 ophthalmic solution

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Allergic Conjunctivitis

Conditions

Allergic Conjunctivitis

Trial Timeline

— → —

NCT ID
NCT01363713

About DE-114 ophthalmic solution

DE-114 ophthalmic solution is a phase 3 stage product being developed by Santen Pharmaceutical for Allergic Conjunctivitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01363713. Target conditions include Allergic Conjunctivitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01363713Phase 3Completed

Competing Products

20 competing products in Allergic Conjunctivitis

See all competitors
ProductCompanyStageHype Score
BriquilimabJasper TherapeuticsPhase 1
25
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
77
Lesigercept + PlaceboYuhanPhase 2
52
YH35324 + Omalizumab + PlaceboYuhanPhase 1
33
Bilastine + Desloratadine + PlaceboYuhanPhase 3
77
ASP2390 + PlaceboAstellas PharmaPhase 1
33
ASP4070 + PlaceboAstellas PharmaPhase 2
52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
52
Prednisolone + VoriconazoleCiplaPhase 2/3
65
placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
85
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
85
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
77
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
77
ciclesonide nasal aerosol + mometasone Aqueous (AQ) nasal spraySumitomo PharmaPhase 1
33
ciclesonide + mometasoneSumitomo PharmaPhase 3
77
DSP-3025 + PlaceboSumitomo PharmaPhase 1
33
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
77

Other Products from Santen Pharmaceutical

Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77